rs2289669 — SLC47A1 MATE1 G-1853A

SLC47A1 encodes MATE1 (multidrug and toxin extrusion protein 1), a transporter that pumps organic cations — including metformin — from renal tubular cells and hepatocytes back into the urine or bile. While OCT1 and OCT2 pull metformin into cells from the bloodstream, MATE1 pushes it out the other side. Together, these transporters determine the net cellular concentration of metformin and, therefore, how powerfully the drug activates its molecular target.

The rs2289669 G>A variant sits in an intron of SLC47A1 on chromosome 17p11.2. The A allele is associated with reduced MATE1 efflux activity, meaning the renal tubular cells hold onto metformin longer before excreting it. This delayed clearance translates into prolonged tissue exposure and, in multiple studies of Chinese and Korean populations, a measurably stronger glucose-lowering response. The effect is not independent of OCT1 genotype at rs622342 — the two transporters are functionally coupled, and their combined genotype determines the full pharmacokinetic picture.

MATE1 is expressed on the apical (urine-facing) membrane of renal proximal tubular cells and on the canalicular membrane of hepatocytes. It functions as an antiporter: it exports organic cations like metformin in exchange for protons flowing inward. By exporting metformin into the renal filtrate and bile, MATE1 completes the cycle that started when OCT2 (in the kidney) and OCT1 (in the liver) imported the drug.

The A allele at rs2289669 reduces MATE1 transporter function, though the exact molecular mechanism is not definitively established. Genomic editing experiments showed that the variant itself does not alter SLC47A1 transcript expression or splicing — it may tag a causal functional variant in linkage disequilibrium, or it may exert regulatory effects not detectable in hepatocellular model systems. Functionally, regardless of mechanism, A allele carriers show reduced renal secretion of metformin: in a controlled Korean study, ranitidine (a competitive MATE1 inhibitor) unmasked a 15.2% lower metformin renal clearance in GA+AA carriers versus GG homozygotes.

The clinical consequence is paradoxical: reduced MATE1 function means more metformin stays in tissues longer, which activates AMPK more durably and suppresses hepatic gluconeogenesis more effectively. In Chinese patients with newly diagnosed type 2 diabetes on metformin monotherapy, the AA genotype produced approximately double the HbA1c reduction of GG carriers. The A allele also appears to amplify the metformin-associated rise in basal GLP-1, suggesting a secondary mechanism beyond direct AMPK activation.

The variant was first linked to metformin response in the Rotterdam Study. Becker et al. 2010¹¹ Becker et al. 2010
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010 found that rs2289669 alone had no significant main effect on HbA1c change in 98 incident metformin users, but showed a statistically significant multiplicative interaction with OCT1 rs622342 (p=0.015). In OCT1 CC homozygotes, the MATE1 A allele was associated with a 0.68% greater HbA1c reduction — the combined impairment of both influx (CC) and efflux (A allele) creating the most dramatic attenuation of transport, and paradoxically the strongest drug retention.

In Chinese patients, associations were stronger and more direct. He et al. 2015²² He et al. 2015
SLC47A1 rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion. Diabetes Obes Metab 2015 conducted a randomized trial in 220 newly diagnosed type 2 diabetes patients with one-year follow-up. AA homozygotes achieved -2.32% HbA1c reduction versus -1.07% in GG carriers — a roughly two-fold difference — attributable to significantly lower urinary metformin excretion (p<0.01). Liang et al. 2017³³ Liang et al. 2017
Differential increments of basal GLP-1 concentration among SLC47A1 rs2289669 genotypes. Diabet Med 2017 replicated the glycemic association in 291 patients and added a mechanistic layer: A allele carriers showed significantly greater metformin-induced rises in basal GLP-1, and when GLP-1 changes were statistically controlled, the rs2289669 effect on HbA1c disappeared — suggesting GLP-1 secretion mediates the genotype-response relationship.

The pharmacokinetic dimension was confirmed in a controlled Korean study. Cho and Chung 2016⁴⁴ Cho and Chung 2016
The MATE1 rs2289669 polymorphism affects renal clearance of metformin following ranitidine treatment. Pharmacogenomics J 2016 showed that 26 healthy subjects with the GG genotype had 15.2% higher renal clearance of metformin after ranitidine administration than GA+AA carriers — demonstrating that co-administration of MATE1 inhibitors (ranitidine, cimetidine, trimethoprim) amplifies the effect of the A allele genotype.

A large meta-analysis by the MetGen consortium found no significant association of rs2289669 with metformin response. Kalamajski et al. 2022⁵⁵ Kalamajski et al. 2022
Genomic editing of metformin efficacy-associated genetic variants in SLC47A1. Eur J Hum Genet 2022 also showed that CRISPR editing of rs2289669 did not alter SLC47A1 expression or splicing. This raises the possibility that the variant tags a causal locus in LD rather than being directly functional, and that effect sizes in smaller studies were inflated. The evidence level is therefore moderate rather than strong or established.

For GG homozygotes, MATE1 function is normal, and metformin clearance is efficient. If type 2 diabetes is well-controlled on standard doses, no pharmacogenomic adjustment is needed. However, MATE1 inhibitor drugs (ranitidine, cimetidine, trimethoprim) can significantly raise metformin plasma levels, and this risk is magnified in GG carriers who rely on normal MATE1 function to maintain clearance.

For AA homozygotes, the reduced efflux means metformin concentrations are higher and more persistent. This confers a pharmacodynamic advantage — better glucose control at standard doses — but also greater susceptibility to metformin accumulation if renal function declines, or if MATE1-inhibiting drugs are co-administered. Monitoring renal function and being cautious with MATE1 inhibitors is especially important for this genotype.

This variant is the final element of the metformin pharmacogenomics panel alongside OCT1 rs622342 (SLC22A1) and ATM rs11212617. OCT1 controls metformin influx into hepatocytes; MATE1 controls efflux. The Rotterdam Study demonstrated a significant multiplicative interaction: the rs2289669 effect on glucose lowering is amplified several-fold in carriers of the OCT1 rs622342 CC genotype compared to AA carriers. The Chinese studies, conducted primarily in East Asian populations where the A allele is more uniformly represented, may partly explain the stronger main effects observed. Clinically, assessing all three variants together provides the most complete picture of predicted metformin response.